Research & Development
Sobi partners with Innate Pharma to advance lacutamab in T-cell lymphoma
10 August 2026 - Biopharmaceutical company Swedish Orphan Biovitrum AB (Sobi) (STO:SOBI) and clinical-stage biotechnology company Innate Pharma SA (Euronext Paris:IPH) (Nasdaq:IPHA) announced on Monda...
Oculis signs agreement to acquire Privosegtor from Accure Therapeutics
10 August 2026 - Switzerland-based biopharmaceutical company Oculis Holding AG (NASDAQ:OCS) (XICE:OCS) announced on Monday that it has entered into an asset purchase agreement with Accure Therapeutics...
Biophytis receives Brazilian approval for Phase 2 obesity trial of BIO101
10 August 2026 - Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) announced on Monday that it has received approval from Brazil's National Health Survei...
ImmuPharma selects Kymos Group as bioanalytical partner for Kapiglucagon
10 August 2026 - Specialist drug discovery and development company ImmuPharma plc (LSE AIM: IMM) announced on Monday that it has selected Kymos Germany/Prolytic, part of Kymos Group, as its bioanalyti...
BioInvent receives FDA Fast Track designation for BI-1808 in ovarian cancer
7 August 2026 - Swedish biotech company BioInvent International AB (STO:BINV) announced on Friday that the US Food and Drug Administration (FDA) has granted Fast Track designation to its first-in-clas...
Galibra Neuroscience's SSADH deficiency gene therapy receives FDA Orphan Drug and Rare Pediatric Disease Designations
6 August 2026 - Biotechnology research company Galibra Neuroscience announced on Wednesday the receipt of both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the US F...